GO
Loading...

Pharmaceuticals

More

  • Novo Nordisk: A Big "No" To Inhaled Insulin--For Now Tuesday, 15 Jan 2008 | 8:11 AM ET

    In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.

  • Genetech

    Genentech reported a profit that rose 6.4 percent and beat forecasts, but sales of all four of the company's main drugs fell short of expectations.

  • Merck And Schering Plough: "Enhancing" A Franchise? Monday, 14 Jan 2008 | 2:13 PM ET

    The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)

  • Merck, Schering: Cholesteral Drug Study Disappoints Monday, 14 Jan 2008 | 10:50 AM ET

    Merck and Schering-Plough said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.

  • Dendreon's Saga Over Provenge "Edited Up" A Notch Friday, 11 Jan 2008 | 1:09 PM ET

    The brouhaha over the Food and Drug Administration's delay of the potential approval of the prostate cancer drug Provenge from the small biotechnology company Dendreon is now entering the prestigious and credible sphere of peer-reviewed scientific journals.

  • Eli Lilly

    Even though I'm back on the East Coast today I wanted to share what I think is an interesting anecdote from my time Monday at the JPMorgan Healthcare Conference which is wrapping up in San Francisco.

  • FDA In 2007: Not Much Love For New Drugs Wednesday, 9 Jan 2008 | 1:52 PM ET

    BioMed Tracker, which closely monitors the clinical trial and drug approval process for investors, is out with a new report today on the Food and Drug Administration's record last year. The drug approval rate went down 13 percent and the number of "approvable letters" went up a whopping 40 percent. An approvable letter has become a euphemism for "delay."

  • Amgen And Me: We're Still On The "Wrong" Foot Tuesday, 8 Jan 2008 | 3:56 PM ET
    AMGEN

    So, imagine my surprise when Amgen put out a press release this morning with new financial guidance. You can read it for yourself here. The release was issued in conjunction with the company's presentation at the JPMorgan Healthcare Conference.

  • FDA Approves Daily Cialis Doses Tuesday, 8 Jan 2008 | 10:34 AM ET

    Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.

  • Genzyme And Isis Steal Show With Cholesterol Drug Tuesday, 8 Jan 2008 | 10:28 AM ET

    After the closing bell Monday, Genzyme and Isis Pharmaceuticals announced a blockbuster deal that set the overcrowded halls abuzz here at the JPMorgan Healthcare Conference. They're partnering on an Isis drug in late-stage development for cholesterol. It's a once-a-week injectable for people who don't get their cholesterol low enough taking a statin like Lipitor, Crestor or Zocor.

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • How to Make Money from Pharma Stocks Monday, 7 Jan 2008 | 9:10 AM ET

    Investors could get good returns in the health-care sector and use it to protect themselves from wild price swings in other areas if they pick the right shares, despite the fact that many big-cap health-care stocks took a battering in 2007, Luis Correia, fund manager at Clariden Leu, told “Squawk Box Europe” Monday.

  • AMGEN

    In a research note to clients this morning, Miller Tabak healthcare analyst Les Funtleyder writes about the FDA news I blogged about yesterday regarding Amgen's anemia drugs. He says, "...we believe the major 'leg down' in usage (of the anemia drugs) was last year and more studies assuming no major new negative revelations will only serve to continue deterioration but at a decelerating rate."

  • Mad Mail: What's the Best Way to Play Spec Stocks? Friday, 4 Jan 2008 | 11:21 AM ET

    Plus, Cramer the Scary Monster and lost faith in Celgene.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Amgen: Anemia Drugs Take Yet Another Hit Thursday, 3 Jan 2008 | 4:18 PM ET

    The Food and Drug Administration late this morning put out a news release with the heading, "FDA Receives New data on Risks of Anemia Drugs." This is more bad news for an additional population of cancer patients and, of course, Amgen and, to a lesser extent, Johnson and Johnson.

  • French Smokers

    Pfizer sent out a press release this morning touting the findings of a company-sponsored European survey of ex-smokers. The study found that 84 percent of the respondents in France, Germany, Italy, Spain and the UK who had consulted with a doctor or some other healthcare professional about quitting thought it was helpful.

  • What Went Wrong in 2007 Thursday, 3 Jan 2008 | 11:06 AM ET

    Cramer’s New Year’s resolution: never to make these mistakes again.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • What Went Right in 2007 Thursday, 3 Jan 2008 | 11:05 AM ET

    Cramer reviews his top picks of the year and the lessons he learned from their success.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Dendreon And Desmond: Flippin' Through The LA Times Wednesday, 2 Jan 2008 | 1:36 PM ET

    The "Dendreonians" have probably already seen it, but I wanted to call your attention to a pretty long piece that ran in the health section of the Los Angeles Times on Dec. 31st. It's about the grass-roots movement to get Dendreon's prostate cancer drug, Provenge, approved by the FDA. Here's the link.

  • AstraZeneca Seeks Seroquel XR Approval Extension Wednesday, 2 Jan 2008 | 8:52 AM ET

    AstraZeneca said on Wednesday it was seeking approval from U.S. regulators to sell an extended-release version of its Seroquel drug to treat both manic and depressive episodes associated with bipolar disorder.